21/09/2010 Catalonian Health Minister opens Collserola Building, VHIR's new facilities 21/09/2010 Catalonian Health Minister, Marina Geli, opened on Wednesday 22 September the new facilities of Vall d'Hebron Research Institute (VHIR), Building Collserola. Building Collserola, made with the support of P.O. FEDER2007-2013, will host nearly 200 scientists in its 2500 m2, and complements the Mediterranean building, the historic VHIR's facilities. The physical expansion with 16 new laboratories and general facilities services, comes in a period of expansion in the Institute's objectives. One of the most important is that VHIR will coordinate, in conjunction with the Instituto de Salud Carlos III, the best Spanish research centers in the European consortium EATRIS. The aim of this network is to join the best translational research in biomedicine in Europe to facilitate the implementation of research findings to patient treatment. In practice, will help to develop new vaccines, offer patients personalized medicine services, expand the supply of drugs available in the market and innovate in advanced therapies, such as cell and gene therapy. Catalonian Health Minister, Marina Geli, opened on Wednesday 22 September the new facilities of Vall d'Hebron Research Institute (VHIR), Building Collserola. Building Collserola, made with the support of P.O. FEDER2007-2013, will host nearly 200 scientists in its 2500 m2, and complements the Mediterranean building, the historic VHIR's facilities. The physical expansion with 16 new laboratories and general facilities services, comes in a period of expansion in the Institute's objectives. One of the most important is that VHIR will coordinate, in conjunction with the Instituto de Salud Carlos III, the best Spanish research centers in the European consortium EATRIS. The aim of this network is to join the best translational research in biomedicine in Europe to facilitate the implementation of research findings to patient treatment. In practice, will help to develop new vaccines, offer patients personalized medicine services, expand the supply of drugs available in the market and innovate in advanced therapies, such as cell and gene therapy. Twitter LinkedIn Facebook Whatsapp